

RECEIVED  
CENTRAL FAX CENTERAppl. No. 10/600,266  
Reply to Office Action of September 11, 2006

DEC 01 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising consisting essentially of 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in a ratio by weight of 1:500 to 500:1 ~~and wherein there is no thromboxane  $A_2$ -receptor antagonist~~ and, optionally, a pharmaceutically acceptable excipient.

2. (Currently Amended) The pharmaceutical composition of claim 1 ~~further comprising a~~ containing said pharmaceutically acceptable excipient.

3. (Original) The pharmaceutical composition of claim 1 wherein the 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.

Appl. No. 10/600,266  
Reply to Office Action of September 11, 2006

4. (Original) The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the hydrochloride.

5. (Original) The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the maleate.

6. (Withdrawn-Currently Amended) A method for the prevention of diseases caused by thrombus or embolus, comprising administering ~~[[a]] the pharmaceutical composition of claim 1 comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their in a pharmacologically effective ~~amounts~~ amount, to a warm-blooded animal.~~

7. (Withdrawn) A method according to claim 6, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

Appl. No. 10/600,266  
Reply to Office Action of September 11, 2006

8. (Withdrawn) A method according to claim 6 or claim 7, in which the warm-blooded animal is a human.

9. (Withdrawn-Currently Amended) A method for the treatment of diseases caused by thrombus or embolus, comprising administering ~~[[a]] the pharmaceutical composition of claim 1 comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their a pharmacologically effective amounts amount, to a warm-blooded animal.~~

10. (Withdrawn) A method according to claim 9, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

11. (Withdrawn) A method according to claim 9 or claim 10, in which the warm-blooded animal is a human.

12. (Withdrawn-Currently Amended) A method for the treatment of a patient undergoing stenting, angioplasty, and/or to prevent restenosis comprising administering ~~[[a]] the pharmaceutical~~

Appl. No. 10/600,266  
Reply to Office Action of September 11, 2006

composition of claim 1 comprising ~~2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their a pharmacologically effective amounts amount, to a warm-blooded animal.~~

13. (Withdrawn) A method according to claim 12, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

14. (Withdrawn) A method according to claim 12 or claim 13, in which the warm-blooded animal is a human.

Claims 15 -19 (Canceled)